veranova

Veranova is a privately held, revenue-generating CDMO that has established itself as a key player in the complex API manufacturing space. The company leverages deep expertise in solid form sciences, particle engineering, and complex chemistry to support the development of novel therapeutics, including ADCs and psychedelics. With over 200 active Drug Master Files (DMFs) and involvement in approximately 15% of FDA-approved small molecule drugs since its founding, Veranova provides an integrated service model from process development to API life cycle management. Its global GMP manufacturing network in the US and UK supports clients from discovery through commercialization.

Integrated CDMO platform specializing in solid form sciences, particle engineering, complex chemistry (HPAPIs, ADC linkers/payloads), and phase-appropriate process/analytical development for API scale-up and manufacturing.

Veranova competes in the global CDMO market against large, diversified players (e.g., Lonza, Catalent) and other niche specialists focused on complex molecules and potent compounds. Its differentiation lies in its deep technical expertise in solid form, HPAPIs, and ADC payloads, combined with a consultative partnership model.